Curiont Issues 21.8 Billion Won in BW and CB to Accelerate Next-Generation ADC Development

Expanding Research on Dual Payload ADC 'QP101' Co-developed with Synaffix
Limited Concerns Over Stock Dilution

Curiont, an innovative drug development company, has decided to issue a total of 21.8 billion won in private placement bonds with warrants (BW) and convertible bonds (CB) to accelerate the development of next-generation antibody-drug conjugates (ADC).

This issuance is aimed at raising operating funds to speed up research and development of core pipelines. The third BW issuance amounts to 9 billion won, while the fourth CB issuance totals 12.8 billion won. Both bonds carry a zero percent coupon rate, a maturity interest rate of three percent, and share the same maturity date of November 6, 2030.

Through this fundraising, Curiont plans to accelerate the development of its dual payload ADC (QP101), which is being co-developed with ADC specialist Synaffix, as well as new ADC projects based on novel payloads.

In particular, QP101 attracted attention when it was presented at the AACR-NCI-EORTC International Conference held in Boston, USA, in October 2025. According to preclinical results, QP101 demonstrated strong and sustained tumor suppression in both Enhertu-refractory and resistant models. It also showed favorable tolerability and pharmacokinetic stability in non-human primate toxicity studies, supporting its potential for clinical entry.

The company explained that the scale of this BW and CB issuance is not significant compared to Curiont's current market capitalization, so concerns about stock dilution are limited. As a result, the company expects to secure the necessary resources to advance its key oncology pipeline into clinical trials and pursue global technology transfer, all while minimizing financial burden.

A Curiont representative stated, "This fundraising is a strategic decision to further strengthen our core anticancer drug research and development. We will expand our global-level ADC platform competitiveness and secure a leading position in the next-generation anticancer drug market."